Top 3 Picks
2026 Outlook
Sector revenue growth is projected to reach mid-single digits through 2026, supported by AI-enabled imaging, robotic-assisted surgery, and expanded access in emerging markets. Orthopedics and minimally invasive platforms should outperform as hospitals prioritize capital equipment upgrades. Margin pressure from raw material costs and reimbursement scrutiny will likely persist, favoring companies with strong pricing power and scale.
Complete Rankings
| Rank | Stock | Score | Price | Market Cap |
|---|---|---|---|---|
|
1
|
West Pharmaceutical Services, Inc.
|
60.7 | $339.97 | $19.5B |
|
2
|
Alphatec Holdings, Inc.
|
60.4 | $9.45 | $2.1B |
|
3
|
Integra LifeSciences Holdings
|
59.0 | $16.72 | $1.1B |
|
4
|
Glaukos Corporation
|
58.1 | $177.47 | $4.8B |
|
5
|
LeMaitre Vascular, Inc.
|
57.0 | $80.67 | $2.0B |
|
6
|
3M Company
|
56.3 | $168.56 | $83.1B |
|
7
|
Teleflex Incorporated
|
54.9 | $138.36 | $5.5B |
|
8
|
Penumbra, Inc.
|
54.6 | $322.17 | $9.7B |
|
9
|
UFP Technologies Inc
|
54.2 | $288.79 | $1.5B |
|
10
|
SS Innovations International Inc. Common Stock
|
53.8 | $3.41 | $1.4B |
|
11
|
Orthofix Medical Inc. Common Stock (DE)
|
52.7 | $9.29 | $566M |
|
12
|
Newegg Commerce, Inc. Common Shares
|
52.0 | $15.32 | $890M |
|
13
|
Insulet Corporation
|
52.0 | $147.48 | $21.5B |
|
14
|
Baxter International Inc.
|
51.7 | $25.83 | $12.0B |
|
15
|
PROCEPT BioRobotics Corporation Common Stock
|
51.1 | $22.76 | $1.9B |
In-Depth Analysis: Top Medical Devices Stocks
WST
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary …
West Pharmaceutical Services is a critical supplier of elastomer-based packaging components, nonglass containment solutions, and auto-injectors to pharmaceutical, biotechnology, and generic drug firms, underpinning safe injectable drug delivery across the Medical Devices sector.
West's 17.0% profit margin and 19.1% ROE reflect strong operational efficiency and returns on equity, backed by 13.8% revenue growth, though the 43.9 P/E signals a premium valuation relative to growth.
Investors should consider WST in 2026 for its 13.8% revenue growth and 19.1% ROE, which position the company to capture rising demand in biologics and generics packaging. Its specialized auto-injector and containment portfolio aligns with expanding injectable drug markets, supporting sustained top-line expansion. The 60.7/100 Tradestie Score combined with 17.0% margins indicates resilience that could drive further valuation upside despite the elevated P/E.
ATEC
Alphatec Holdings Inc is a medical technology company focused on the designing, development, and advancement of products for the surgical treatment of spinal disorders associated with disease and degeneration, congenital deformities, and trauma. The company's spine approach technologies include Posterior Cervical Fusion, Anterior Cervical Discectomy and Fusion, Lateral Interbody Fusion, and Posterior Lumbar Interbody Fusion among others.
Alphatec Holdings, Inc. develops specialized spine surgery technologies for treating spinal disorders from disease, degeneration, deformities, and trauma, positioning it as a key innovator in the medical devices sector's spinal implant market.
A profit margin of -13.5% and ROE of -373.4% reflect persistent losses and weak capital efficiency, offset partially by 15.1% revenue growth and a 60.4/100 Tradestie Score.
Revenue expansion at 15.1% in the growing spinal devices segment, paired with a 60.4/100 Tradestie Score, supports potential market share gains through posterior approach innovations. Scaling these technologies could narrow margins and improve ROE by 2026 as procedure volumes rise. Investors targeting medical device growth stories may find entry attractive ahead of anticipated operating leverage.
IART
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it …
Integra LifeSciences matters in the Medical Devices sector through its Codman specialty surgical and tissue technologies segments, which supply regenerative therapies, extremity orthopedics, and neurosurgical devices for critical surgical applications.
Integra reports a -0.4% profit margin and -0.7% ROE alongside 0.8% revenue growth, reflecting ongoing pressures on margins and returns that indicate weak operational leverage across its two segments.
IART offers a 2026 entry point for investors due to its established position in neurosurgical and regenerative markets where procedure volumes are expanding. A Tradestie score of 59.0/100 combined with modest revenue growth provides a base for margin recovery if the Codman segment executes on cost controls. Sector demand for specialty surgical devices could lift returns above current negative levels within two years.
GKOS
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. …
Glaukos Corporation advances dropless ophthalmic therapies in the Medical Devices sector, targeting glaucoma, corneal disorders, and retinal diseases through novel products like iDose TR that reduce reliance on traditional eye drops.
GKOS shows -30.7% profit margin and -26.0% ROE despite 49.5% revenue growth, reflecting heavy commercialization spending that sustains negative returns while scaling operations.
iDose TR commercialization could drive sustained 49.5%+ revenue expansion into 2026, enabling margin expansion from current -30.7% levels as adoption scales in glaucoma treatment. The 58.1/100 Tradestie Score combined with sector demand for minimally invasive devices supports potential ROE improvement above -26.0% as fixed costs leverage higher volumes.
LMAT
LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include …
LeMaitre Vascular, Inc. specializes in medical devices for peripheral vascular disease treatment during open surgery, targeting key areas including carotid, lower extremities, upper extremities, and aorta within the Medical Devices sector.
LMAT delivers strong profitability with a 25.0% profit margin and 16.8% ROE, backed by 9.6% revenue growth that supports efficient capital returns in a specialized device niche.
LMAT's 25.0% margins and 9.6% revenue growth provide a foundation for sustained expansion in vascular surgery devices through 2026. Its 16.8% ROE and 28.1 P/E suggest efficient operations at a valuation aligned with sector growth in peripheral treatments. Investors may target the stock for compounding returns from consistent financial metrics.
MMM
3M, a multinational conglomerate founded in 1902, sells tens of thousands of products ranging from sponges to respirators. The firm is well known for its extensive research and development capabilities, and it is a pioneer in inventing new use cases for its proprietary technologies. 3M is organized across three business segments: safety and industrial (representing around 44% of revenue), transportation …
3M matters in Medical Devices through its Health Care segment, which supplies respirators, wound care products, and sterilization solutions derived from proprietary adhesive and material technologies across tens of thousands of SKUs.
3M posts an 11.9% profit margin and exceptional 81.9% ROE on 2.5% revenue growth, reflecting strong operational leverage and capital efficiency, though the 30.2 P/E ratio indicates the market prices in sustained high returns.
With a Tradestie Score of 56.3/100 and proven R&D pipeline, 3M offers upside in 2026 from new medical device applications in infection prevention and diagnostics, potential ROE maintenance above 70%, and re-rating potential if revenue growth accelerates above 3% amid sector demand recovery.
TFX
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2024 sales), interventional (19%), anesthesia (13%), surgical (15%), interventional urology (11%), original-equipment manufacturing (11%), and other (7%). Geographic exposure for the business is primarily in the US, which accounts for …
Teleflex Incorporated contributes to the Medical Devices sector as a key provider of vascular access and interventional devices, representing 43% of its 2024 sales, essential for bloodstream and surgical applications in hospitals.
With a profit margin of -45.8% and ROE of -0.7%, Teleflex demonstrates significant profitability challenges despite 28.9% revenue growth, suggesting operational inefficiencies or extraordinary expenses impacting financial health.
Investors may consider TFX for 2026 due to its robust revenue expansion across diversified segments like vascular access and surgical products. The company's focus on high-demand medical areas positions it for market recovery and margin improvement. A Tradestie Score of 54.9/100 indicates moderate potential amid sector growth.
PEN
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.
Penumbra, Inc. matters in the Medical Devices sector as a specialist in thrombectomy and embolization devices that mechanically remove blood clots, selling minimally invasive solutions primarily to hospitals and physicians in acute care settings.
Penumbra shows moderate profitability with a 10.7% profit margin and 11.4% ROE alongside 14.9% revenue growth, though the P/E of 79.3 signals premium valuation and the Tradestie Score of 54.6/100 reflects average sector positioning.
Investors should consider buying PEN in 2026 due to its 14.9% revenue growth in the thrombectomy market. Margin expansion beyond the current 10.7% profit margin and ROE lift above 11.4% could be driven by acute care demand and US-based device innovation. The 79.3 P/E may be supported by sustained market share gains in embolization equipment.
UFPT
UFP Technologies Inc is a designer and custom manufacturer of components, subassemblies, products, and packaging utilizing specialized foams, films, and plastics for the medical market. The company manufactures its products by converting raw materials using laminating, molding, radio frequency and impulse welding, and fabricating manufacturing techniques. It is an important link in the medical device supply chain and a valued …
UFP Technologies supplies custom-engineered foam, film, and plastic components and subassemblies critical to medical device packaging and manufacturing, supporting specialized production processes like laminating, molding, and radio frequency welding for healthcare applications.
With an 11.5% profit margin and 17.1% ROE alongside 15.1% revenue growth, UFP Technologies exhibits solid profitability and efficient capital returns, though its 31.7 P/E ratio signals elevated valuation relative to earnings.
UFPT's 15.1% revenue growth and 17.1% ROE position it to capture expanding demand for medical-grade components through 2026, potentially driving further margin gains from scale in specialized manufacturing. Investors may benefit from sustained healthcare sector tailwinds that reward its niche expertise in custom foams and plastics.
SSII
SS Innovations International Inc is a commercial-stage surgical robotics company focused on transforming patient lives by democratizing access to advanced surgical robotics technologies. The company designs, manufactures, and markets an advanced, next-generation, and affordable surgical robotic system called the SSi Mantra, and the instruments and accessories used with SSi Mantra to perform a wide range of soft-tissue, robotically assisted surgeries. …
SS Innovations International Inc. stands out in the Medical Devices sector by developing affordable next-generation surgical robotic systems, aiming to democratize access to advanced technologies and transform patient outcomes in surgical procedures.
The company reports a -23.7% profit margin and -26.1% ROE, signaling ongoing losses amid development phases. Its 39.4% revenue growth highlights improving top-line performance in the medical devices space.
The 39.4% revenue growth and focus on affordable robotics present a compelling opportunity for market expansion by 2026. With a Tradestie Score of 53.8/100, SSII offers moderate risk for investors seeking exposure to surgical innovation. Scaling could drive profitability improvements as adoption increases.
Methodology
Stocks are ranked using the Tradestie Score, a proprietary 0-100 rating that combines fundamental quality (profitability, balance sheet strength), growth metrics (revenue and earnings growth), valuation (P/E, PEG ratio), and momentum factors. Scores are updated daily based on the latest market data. Learn more about our methodology.